The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback